MedTrace Logo

A Study to Evaluate the Efficacy and Safety of AD-218

NCT05400317 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 520

Last updated 2025-02-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of AD-218

Conditions

  • Mixed Dyslipidemia

Interventions

DRUG

AD-218

PO, Once daily(QD), 12weeks

DRUG

AD-218A

PO, Once daily(QD), 12weeks

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Principal Investigators

  • Kyu Chang Won, M.D., Ph.D · Yeungnam University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-27
Primary Completion
2026-03-31
Completion
2026-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05400317 on ClinicalTrials.gov